Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed Revision: v3.5.0 from the page.
    Difference
    0.1%
    Check dated 2026-04-16T10:19:16.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed.
    Difference
    0.1%
    Check dated 2026-03-25T19:02:08.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.3, replacing the previous v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T14:39:35.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the previous notices (funding lapse notice and Revision: v3.4.1). This is an administrative update and does not affect the trial information or how users interact with the page.
    Difference
    0.4%
    Check dated 2026-02-11T02:07:58.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status, including guidance that information may not be up to date. Also updated the site version to Revision: v3.4.1 and removed the previous Revision: v3.4.0 tag.
    Difference
    0.4%
    Check dated 2026-02-03T23:48:19.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    UI/metadata updates (glossary toggle, 'Last Update Submitted that Met QC Criteria' label, and footer changes 'No FEAR Act Data' and 'Revision: v3.4.0') do not affect core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-27T17:46:04.000Z thumbnail image

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.